Elutia (ELUT) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Elutia (ELUT) has outperformed Tevogen (TVGN) over the past year, losing 6.9% versus a loss of 80.5%. Tevogen is the larger company by market cap ($46.0 million vs $36.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELUT | TVGN |
|---|---|---|
| Share price | $0.8273 | $7.06 |
| Market cap | $36.64M | $45.97M |
| 1-day change | +0.88% | +8.78% |
| YTD return | +19.38% | -57.34% |
| 1-year return | -6.94% | -80.50% |
| 5-year return | -84.82% | — |
| EPS (TTM) | $-0.64 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.39 | $39.00 |
| 52-week low | $0.50 | $3.64 |
| Distance from 52-week high | -40.27% | -81.90% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +504.38% | — |
| Average volume | 185.82K | 10.03K |
| Shares outstanding | 44.29M | 6.51M |
| Employees | 25 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed TVGN by 73.6 percentage points over the past year.
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Healthcare · Medical Devices · 25 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Healthcare · Biotechnology · 18 employees
ELUT vs TVGN FAQ
Which is bigger, Elutia or Tevogen?
Tevogen (TVGN) is larger, with a market capitalization of $45.97M compared with $36.64M for Elutia (ELUT).
Which stock has performed better over the past year, ELUT or TVGN?
ELUT returned -6.94% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Elutia and Tevogen in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Elutia and Biotechnology for Tevogen.